TNKASE (tenecteplase) Patient Assistance Program
Don’t let the high cost of brand thrombolytic therapy disrupt your emergency cardiac/stroke care. We help eligible patients access TNKase (tenecteplase) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- TNKase (tenecteplase) is FDA-approved for the reduction of mortality associated with acute ST-elevation myocardial infarction (STEMI) and for acute ischemic stroke in adults. It is a recombinant tissue plasminogen activator (tPA) with single-bolus dosing (vs. the 60-minute infusion required for alteplase/Activase).
- Without assistance, TNKase costs commonly run approximately $4,500–$7,000 per single dose.
- Through AffordMyPrescriptions, qualifying patients can access TNKase for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of TNKase in the U.S. as of 2026. The other tPAs for AMI/stroke include alteplase (Activase — 60-minute infusion) and reteplase (Retavase — two boluses 30 min apart). TNKase's single-bolus dosing makes it operationally simpler and is increasingly preferred for both STEMI and acute ischemic stroke in many centers.
What Is TNKase Prescription Assistance Program?
The TNKase Prescription Assistance Program is a manufacturer-sponsored initiative that provides TNKase at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for emergent thrombolytic therapy in patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, ER/cardiology/neurology coordination, prior-authorization documentation (typically retrospective for emergency use), and hospital billing.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment for TNKase coverage — especially important for patients facing large hospital bills after emergency thrombolytic therapy.
Pharmacy Price Comparison
- Without assistance, TNKase costs roughly $4,500–$7,000 per single dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Hospital pharmacy | ~$6,500/dose | Save substantially |
| Inpatient billing | ~$7,000/dose | Save substantially |
| Specialty Pharmacy | ~$5,500/dose | Save substantially |
| Manufacturer direct | ~$5,000/dose | Save substantially |
GoodRx Best Price | ~$4,500/dose | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your TNKase Prescription Program?
The Patient Assistance Program is free to apply for and provides TNKase at no medication cost if approved. Our $69.95/month service covers full advocacy — especially valuable when facing a large hospital bill from emergency thrombolytic therapy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for TNKase:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $4,500–$7,000 per dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for TNKase assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid TNKase Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding TNKase:
TNKase (tenecteplase) is a genetically modified version of human tissue plasminogen activator (tPA) — a thrombolytic agent used in acute ST-elevation myocardial infarction (STEMI) and acute ischemic stroke. The key advantage over alteplase is single-bolus IV dosing (over 5 seconds) — making it operationally simpler in time-critical emergencies.
How TNKase Works:
Both STEMI and acute ischemic stroke are caused by blood clots blocking critical arteries, and thrombolytics work by pharmacologically dissolving these clots to rapidly restore blood flow. Tenecteplase is a modified version of alteplase designed with a longer half-life, higher fibrin specificity, and resistance to inactivation. These changes allow it to be given as a single fast bolus rather than a prolonged infusion, making it operationally simpler. It is used to open blocked coronary arteries in STEMI when prompt procedures are unavailable, and it is an increasingly preferred, highly effective treatment for ischemic stroke within 4.5 hours of onset.
Form and use:
Tenecteplase is administered as a single intravenous bolus delivered quickly over five seconds. The medication comes as a lyophilized powder that must be reconstituted with sterile water, with dosing determined by the patient’s weight. For STEMI treatment, patients typically receive accompanying heparin and antiplatelet therapies as part of their care protocol. Conversely, when treating an ischemic stroke, concurrent anticoagulants are withheld for the first 24 hours, and antiplatelet therapy may be delayed.
Generic availability:
As of 2026, there is no biosimilar version of tenecteplase available in the United States. Other tissue plasminogen activators on the market include alteplase and reteplase, though reteplase is not approved for treating stroke. While the financial cost across these different options is roughly similar, tenecteplase provides a major practical advantage through its simple single-bolus dosing. Because it avoids the complex weight-based infusion protocols required by alteplase, many medical centers have officially switched to tenecteplase for stroke care.
Warnings:
The most common serious adverse event associated with tenecteplase is bleeding, which includes the risk of life-threatening intracranial hemorrhage. Due to this risk, it is strictly contraindicated in patients with active bleeding, severe uncontrolled hypertension, recent strokes, aneurysms, or recent brain and spinal surgeries. Other potential medical complications include rare cholesterol embolisms and hypersensitivity reactions like angioedema, particularly for patients taking ACE inhibitors. Finally, patients being treated for STEMI frequently experience benign reperfusion arrhythmias as blood flow returns to the heart.
FAQ (Frequently Asked Questions)
How Much Does TNKase Cost Without Insurance?
TNKase costs approximately $4,500–$7,000 per single dose at hospital pricing. Through AffordMyPrescriptions, qualifying patients receive TNKase coverage at no medication cost — our $69.95 monthly fee covers full advocacy and program management. This is especially valuable when facing a large hospital bill from emergency thrombolytic therapy.
Was TNKase Used For My Heart Attack Or Stroke?
TNKase is used in two main emergency scenarios: STEMI (when primary PCI is not feasible within 90 minutes), and acute ischemic stroke (within 4.5 hours of onset, in eligible patients without exclusion criteria). The single-bolus dosing makes TNKase faster to administer than alteplase’s infusion — important for both indications where minutes count.
How Is TNKase Different From Activase (Alteplase)?
Both are tissue plasminogen activators. Alteplase (Activase) is the original — given as a 60–90 minute infusion. Tenecteplase (TNKase) is a genetically modified version with longer half-life, given as a single 5-second bolus. For STEMI, tenecteplase has long been a preferred fibrinolytic. For acute ischemic stroke, recent randomized trials have shown tenecteplase is at least as effective as alteplase and operationally simpler — many stroke centers now use TNKase as first-line.
What About Bleeding Risk?
Bleeding — including intracranial hemorrhage — is the most serious risk of thrombolytic therapy. Strict eligibility criteria minimize the risk. Absolute contraindications include recent stroke, intracranial bleed history, recent major surgery or trauma, severe hypertension, suspected aortic dissection, active bleeding, bleeding disorders. Even with careful patient selection, intracranial hemorrhage occurs in 1–6% depending on indication. The trade-off vs. clinical benefit (saved myocardium, salvaged brain) typically favors thrombolysis in eligible patients.
Can I Get Help With The Hospital Bill?
Yes — that’s exactly when our advocacy is most valuable. Hospital bills for emergency thrombolytic administration can be substantial — even with insurance. The manufacturer’s PAP can retrospectively cover the medication cost for eligible uninsured/underinsured patients, and various charity care programs at hospitals may apply. Our team helps coordinate these resources.
Will I Need TNKase Again?
TNKase is given for acute events (STEMI, acute ischemic stroke) — typically a single dose. Long-term, ongoing antiplatelet therapy (aspirin, clopidogrel/Plavix, ticagrelor/Brilinta), statins, and other cardiovascular medications are usually started. Some patients may eventually need additional procedures (PCI for residual coronary disease, carotid intervention for stroke). Discuss long-term care with your cardiologist or neurologist.
What If My Application Is Denied?
If denied, we explore alternatives — hospital charity programs, the manufacturer’s copay program for commercially insured patients, payment plans through the hospital, and independent foundations such as the American Heart Association, National Stroke Association, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are facing a large bill from TNKase administration during a heart attack or stroke, our team may be able to help you access assistance programs. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.